Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12359094 | 1.00 | NPSR1 (0.33) | NPSR1FPR2SCN9AUSP30 | |
| SCHEMBL13536981 | 1.00 | NPSR1 (0.33) | NPSR1FPR2SCN9AUSP30 | |
| SCHEMBL12359315 | 0.93 | NPSR1 (0.33) | NPSR1USP30 | |
| SCHEMBL12359096 | 0.86 | NPSR1 (0.33) | NPSR1FPR2SCN9A | |
| SCHEMBL12333624 | 0.86 | NPSR1 (0.33) | NPSR1FPR2SCN9A | |
| SCHEMBL348546 | 0.85 | NPSR1 (0.33) | NPSR1FPR2SCN9AUSP30 | |
| SCHEMBL12318935 | 0.82 | NPSR1 (0.37) | NPSR1 | |
| SCHEMBL12373151 | 0.81 | NPSR1 (0.39) | NPSR1FPR2SCN9A | |
| SCHEMBL12359025 | 0.80 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL12306140 | 0.79 | NPSR1 (0.39) | NPSR1FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110223131-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110223131-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7998950-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110223131-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NPSR1 4462/4885FPR2 4293/4885SCN9A 4474/4885 |
| US-20100022508-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NPSR1 4462/4885FPR2 4293/4885SCN9A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.